Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 21-year-old male managed to control his hair loss using Nizoral, RU58841, and finasteride, but experienced increased scalp itchiness after starting creatine, which subsided upon stopping creatine. Users shared mixed experiences on whether creatine affects hair loss, with some reporting negative effects and others seeing no change or defending its benefits.

A 36-year-old man restarted hair loss treatment after a break, using topical Minoxidil 5% twice daily, topical Finasteride 0.01% daily, and Ketoconazole 2% three times a week, along with supplements like Vitamin B12, D3, C, Biotin, Omega-3, zinc, and copper. He avoids oral Finasteride due to side effects and plans to evaluate progress after a year.

2-deoxy-D-ribose is being explored as a hair loss treatment but is not proven effective in humans and may be costly and inconvenient. Minoxidil remains the most effective treatment.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

A user achieved significant hair regrowth from Norwood 3 to a dense Norwood 2 after five months using oral dutasteride, oral minoxidil, and a topical solution with minoxidil, retinoic acid, and hydrocortisone. The user reported no side effects and found the topical treatment especially effective for the hairline.

A user is experiencing severe dandruff and hair loss, considering using ketoconazole shampoo 2% to manage these issues. They seek advice on application frequency and effectiveness, with suggestions to use it 2-3 times a week and to consider other treatments like finasteride for hair loss.

The user experienced significant hair regrowth after 7 months using 1mg finasteride and 2.5mg oral minoxidil, with initial lightheadedness as the only side effect. The user feels more confident and believes the minoxidil contributed most to the regrowth.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The user experienced tiny vellus hairs from 0.5mg finasteride and 2.5mg minoxidil over 9 months. Topical minoxidil, alfatradiol, and RU58841 applied twice daily for 1.5 months significantly improved temple hair regrowth.

Significant hair regrowth was achieved over six years using Minoxidil, Finasteride, and daily 0.25mm dermarolling. Finasteride had the most significant impact, with no reported side effects.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

Excessive use of Nizoral can lead to dry, brittle hair and is not recommended more than 1-2 times a week. Users suggest using conditioner to mitigate dryness and note that Nizoral is more effective for treating fungal issues rather than regrowing hair.

Dutasteride and oral minoxidil improved the user's hair thickness, darkness, and curliness, making them look more attractive and younger. The user takes 0.5mg of dutasteride and 2.5mg of minoxidil daily.

People have been using finasteride for 10 to 20+ years to maintain their hairline, with many reporting success and no significant side effects. Some users have combined finasteride with minoxidil for better results, and a few have switched to dutasteride or added hair transplants when finasteride was less effective.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

A 37-year-old user shared their positive 3-month progress using a topical solution of 5% minoxidil and 0.25% finasteride, combined with weekly microneedling and Nizoral shampoo. They reported no significant side effects and emphasized the importance of consistency and microneedling for hair regrowth.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Young men are advised to delay hair transplants until after age 25, using finasteride, minoxidil, and dermarolling to manage hair loss. Concerns about unethical doctors highlight the need for careful planning.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

Hair regrowth from treatments like finasteride, dutasteride, and minoxidil can take several years, with most visible results appearing within 1-2 years and potential improvements continuing up to 10 years. Consistency and patience are crucial for achieving maximum hair thickness, as hair miniaturization and regrowth are gradual processes.

Sugary beverages increase the risk of pattern hair loss in men by 57%, and type 2 diabetes is linked to female pattern hair loss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hair loss.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The conversation is about using a trivitamin oil mix (Vitamin E, D3, A, Argan Oil, Sunflower Oil) for hair thinning and whether it is safe to apply it after derma rolling. It is advised to wait 12-24 hours after derma rolling before applying any products to avoid infections or allergic reactions.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.